

LEGISLATIVE FISCAL OFFICE **Fiscal Note**

Fiscal Note On: **HB** 436 HLS 15RS 1296

Bill Text Version: **REENGROSSED**

Opp. Chamb. Action: W/ SEN FLOOR AMD

Proposed Amd.:

REVISED Sub. Bill For.:

Date: June 9, 2015 9:37 AM

Dept./Agy.: Department of Health and Hospitals, Board of Pharmacy

Author: JOHNSON, R.

Page 1 of

Analyst: Alan M. Boxberger **Subject:** Provides for insurance reimbursement of certain fees

REF SEE FISC NOTE GF EX See Note

Provides for insurance reimbursement of certain provider fees paid by pharmacies

Present law allows for the Department of Health and Hospitals to impose a fee of up to \$0.10 per prescription for prescription services provided by the Medicaid program. Proposed law requires health insurance issuers to reimburse pharmacies or pharmacists for the payment of the fee when the pharmacy or pharmacist makes a claim for reimbursement of the fee; has no effect to the extent that any sums otherwise certifiable by the state as a component of its share of expenditures in the medical assistance program cannot be certified; provides that any failure to reimburse a pharmacist or his agent shall be an act for which the health insurance issuer or its agent may be sanctioned by the Commissioner of Insurance; and provides for

administrative hearings.

INSURANCE/HEALTH

Senate Floor Amendment 3212 by Senator Mills inserted the entire text of the re-reengrossed version of SB 163. See page 2, Description

EXPENDITURES	2015-16	2016-17	2017-18	2018-19	2019-20	5 -YEAR TOTAL
State Gen. Fd.		SEE BELOW	SEE BELOW	SEE BELOW	SEE BELOW	
Agy. Self-Gen.	\$0	\$0	\$0	\$0	\$0	\$0
Ded./Other	\$0	\$0	\$0	\$0	\$0	\$0
Federal Funds		SEE BELOW	SEE BELOW	SEE BELOW	SEE BELOW	
Local Funds	<u>\$0</u>	<u>\$0</u>	<u>\$0</u>	<u>\$0</u>	<u>\$0</u>	<u>\$0</u>
Annual Total	\$0					\$0
REVENUES	2015-16	2016-17	2017-18	2018-19	2019-20	5 -YEAR TOTAL
State Gen. Fd.	\$0	\$0	\$0	\$0	\$0	\$0
Agy. Self-Gen.	\$0	\$0	\$0	\$0	\$0	\$0
Ded./Other	\$0	\$0	\$0	\$0	\$0	\$0
Federal Funds	\$0	\$0	\$0	\$0	\$0	\$0
Local Funds	<u>\$0</u>	<u>\$0</u>	<u>\$0</u>	<u>\$0</u>	<u>\$0</u>	<u>\$0</u>
Annual Total	\$0	\$0	\$0	\$0	\$0	\$0

EXPENDITURE EXPLANATION

There is no anticipated direct material effect on governmental expenditures as a result of the original proposed law as detailed in the non-amended, Reengrossed version of HB436.

Senate Floor Amendment 3212 by Senator Mills inserted the entire text of the Re-reengrossed version of SB 163.

Proposed law is anticipated to result in additional cost to DHH, potentially up to \$7.9M in FY17 and future fiscal years as a result of correcting certain identified underpayments to pharmacy providers in the pharmacy program. Proposed law requires that the full cost of this measure is the responsibility of DHH through reallocation of existing budget resources of the department and not through additional appropriations. Information provided by the department indicates to the extent there are pharmacy related savings in Bayou Health in future years associated with rate setting, such savings would be utilized to cover any additional costs of the pharmacy changes resulting from this bill. To the extent these savings to not materialize in subsequent years in an amount to offset the cost of this measure, such costs would have to be covered through reallocation of funding in Medical Vendor Payments.

Proposed law requires DHH to set up a reimbursement dispute process related to pharmacy reimbursements paid from managed care organizations to pharmacy providers. In the event the dispute process results in a finding that a reimbursement is unreasonable (as determined by DHH or a party agreed upon by DHH, La. Association of Health Plans, and the La. Independent Pharmacies Association), the MCO must pay the pharmacy an increased reimbursement, presumably to the reasonable amount. Although the bill does not define reasonable, the fiscal note assumes this rate floor (reasonable rate) to be the Fee for Service pricing for these disputed claims. To the extent a reasonable reimbursement would be less than the amount reimbursed under FFS, the cost impact reflected in this note would be reduced.

Estimates provided by Mercer (DHH rate actuary) indicate a projected fiscal impact totaling \$7,960,000 in additional Medicaid <u>costs in FY 17 as a result of this measure</u>. Table 1 below reflects the total estimated impact for FY 17.

EXPENDITURE EXPLANATION CONTINUED ON PAGE 2

REVENUE EXPLANATION

There is no anticipated direct material effect on governmental revenues as a result of this measure.

<u>Senate</u>	Dual Referral Rules	<u>House</u>	\mathbf{x} 6.8(F)(1) >= \$100,000 SGF Fiscal Cost {H & S}	a an Ter
x 13.5.1 >=	\$100,000 Annual Fiscal Cost {	(S&H)	$6.8(F)(2) >= $500,000 \text{ Rev. Red. to State } \{H \& S\}$	John D. Capater
13.5.2 >=	\$500,000 Annual Tax or Fee Change {S&H}			John D. Carpenter Legislative Fiscal Officer



LEGISLATIVE FISCAL OFFICE Fiscal Note

Fiscal Note On: **HB 436** HLS 15RS 1296

Bill Text Version: **REENGROSSED**Opp. Chamb. Action: **W/ SEN FLOOR AMD**

Proposed Amd.:

Sub. Bill For.: REVISED

Date: June 9, 2015 9:37 AM Author: JOHNSON, R.

Dept./Agy.: Department of Health and Hospitals, Board of Pharmacy

Subject: Provides for insurance reimbursement of certain fees

Analyst: Alan M. Boxberger

CONTINUED EXPLANATION from page one:

Page 2 of 2

DESCRIPTION CONTINUED FROM PAGE 1

Proposed law provides that a managed care organization may negotiate the ingredient cost reimbursement in its contracts with certain pharmacy providers (the class of pharmacies with fewer than 10 retail outlets under its corporate umbrella domiciled in at least one Louisiana parish) that contracts with a managed care organization. Proposed law provides for a reimbursement dispute process for such pharmacies to ensure that the reimbursement was reasonable. The process must include at a minimum the following: a) final review authority is maintained by DHH or a party agreed upon by DHH, the La Association of Health Plans, and the La Independent Pharmacies Association; b) if reimbursement is considered unreasonable, the MCO must be required to provide the pharmacy an increased reimbursement and update its maximum allowable cost list to reflect the increase, and c) DHH must define reasonableness in relation to the contractual rate paid by DHH. Proposed law requires that DHH shall not amend any contract with an MCO to comply with this measure (with exceptions). Proposed law provides that after June 15, 2016, no MCO shall pay a Local Pharmacy a per prescription reimbursement at a rate less than legacy Medicaid rate unless its contract with DHH provides for a reimbursement dispute process. Proposed law requires full cost of this measure is the responsibility of DHH through reallocation of existing budget resources and not additional appropriations.

EXPENDITURE EXPLANATION CONTINUED FROM PAGE 1

Table 1

Pharmacy claims impact

Claim	Claim	MCO	Original Avg.	Estimated new	Estimated	Estimated Annual
<u>Type</u>	<u>Count</u>	Original Spend	Claims Cost	Avg. Claim Cost	New Spend	Savings/(Cost)
Brand	68,000	\$18,260,000	\$266.55	\$271.40	\$18,590,000	(\$330,000)
Generic	425,000	\$11,440,000	\$26.94	\$30.39	\$12,910,000	(\$1,470,000)
Specialty	9,000	\$18,400,000	\$2,034.62	\$2,049.47	\$18,540,000	(\$140,000)
Unknown	10,000	<u>\$490,000</u>	<u>\$47.10</u>	<u>\$52.46</u>	<u>\$540,000</u>	(\$50,000)
Quarter	512,000	\$48,590,000	\$94.90	\$98.79	<u>\$50,580,000</u>	<u>(\$1,990,000)</u>
Ann. Total	2,048,000	\$194,360,000	\$94.90	\$98.79	\$202,320,000	(\$7,960,000)

Assumptions/calculations:

- 1. Results based on analysis of third quarter of 2014 (sample period) claims data, annualized
- 2. The impact is based on the assumption that in practice, the Fee For Service pricing schedule will serve as the reasonable reimbursement for disputed claims
- 3. Approximately 541 unique pharmacies identified as having fewer than 10 corporate locations in Louisiana (account for 45% of total claim volume in the sample period
- 4. Mercer calculated average claim cost for the sample period for brand, generic, specialty, and other/unknown category.
- 5. Original paid amount in table above reflects Managed Care claims cost (rounded).
- 6. Revised claim cost assumes what amount would have been paid by MCO under Fee for Service methodology.
- 7. Fee for Service Reimbursement methodology maximum allowable payment is based on the lessor of: The pharmacy's Usual and Customary (U&C) charge minus a Copay, or: Average Acquisition Cost (AAC) + \$10.51 Dispensing Fee (DF) minus a Copay, or: If no AAC, Wholesale Acquisition Cost (WAC) + \$10.51 Dispensing Fee minus a Copay

Depending on the level of disputes, DHH anticipates 1 additional employee will be required to staff a new process for provider appeals of MCO pharmacy reimbursement rates. Projected salary (\$60,000) and related benefits (\$40,000) for a new coordinator in DHH, Medicaid Pharmacy is anticipated to be approximately \$100,000.

<u>Senate</u>	Dual Referral Rules	<u>House</u>	\mathbf{x} 6.8(F)(1) >= \$100,000 SGF Fiscal Cost {H & S}	a a ter
X 13.5.1 >=	= \$100,000 Annual Fiscal Cost	{S&H}	\Box 6.8(F)(2) >= \$500,000 Rev. Red. to State {H & S	John D. Copater
13.5.2 >=	= \$500,000 Annual Tax or Fee Change {S&H}		6.8(G) >= \$500,000 Tax or Fee Increase	John D. Carpenter Legislative Fiscal Officer